Glycans, Inflammation and Cardiovascular Disease: A Modifiable Risk Factor for Long-Term Heart Health

Cardiovascular disease remains the leading cause of death worldwide, yet the biological process that drives most of it, chronic low-grade inflammation, rarely shows up on a standard blood panel until damage is already underway. Cholesterol and blood pressure tell you about mechanical and metabolic risk. They do not tell you how your immune system is ageing, or how much silent inflammatory pressure is building in your blood vessels years before a diagnosis arrives.

This is where glycans, the complex sugar molecules attached to proteins throughout the body, offer something genuinely different. Research spanning cohorts of tens of thousands of people has shown that glycan changes on antibodies and other circulating proteins are associated with cardiovascular risk factors and future cardiovascular events, sometimes years before clinical symptoms appear. That research is what GlycanAge translates into a measurable, trackable signal: an at-home test that reads chronic inflammation through IgG glycosylation, the pattern of sugar structures attached to Immunoglobulin G.

Cardiovascular risk is not fixed by genetics or age alone. It is substantially shaped by inflammaging, the chronic, low-grade inflammation that accumulates in the body over time, and inflammaging is modifiable. Understanding how glycans connect to heart health gives readers and clinicians a biomarker they can act on, not just observe.

New to how glycans work? Start here: Glycans: The Sugars That Reveal Your Biological Age and Immune Health

How are glycans linked to cardiovascular disease risk?

Glycans attach to proteins and lipids throughout the body, and they directly regulate the biological processes that drive cardiovascular disease. This is not a passive relationship: research shows glycans impact hormone signalling, ion channel function, immune cell behaviour, lipoprotein structure, endothelial cell function, and plasma protein stability, all of which play into cardiovascular pathology.

The clinical evidence base for this is substantial. A study of IgG glycosylation across two independent cohorts found glycosylation profiles associated with cardiovascular disease risk scores and subclinical atherosclerosis, the buildup of plaque in artery walls before symptoms appear. Separately, N-glycosylation of IgG has been shown to reveal incident hypertension years in advance, and a large study published in Diabetes Care identified IgG glycosylation signatures in incident type 2 diabetes and cardiovascular disease, reinforcing that the two conditions share overlapping inflammatory biology detectable through glycans.

Perhaps most striking is the timeline. Across the diseases studied, glycan-based models have flagged shifts 6 to 10 years before diagnosis: a 6.3-year lead time for hypertension using IgG glycan traits, an 8.3-year lead time for cardiovascular and cerebrovascular events when combining plasma glycans with the AHA cardiovascular risk score, and 6.5 years for type 2 diabetes, depending on the model. This is the practical argument for glycans as an early biomarker: the biology is moving long before a diagnosis would be made through conventional pathways.

Glycans vs. traditional inflammatory markers

Glyc A, a specific glycan-based signal measured by nuclear magnetic resonance spectroscopy, has been directly compared against standard cardiovascular risk markers. In a study of 28,000 women followed for over 17 years, elevated Glyc A was associated with a higher future risk of heart attack and stroke, even decades later.

"That's really the first report of this Glyc A signal, and then, fast forward now to about two decades later, we were able to measure it on a lot of individuals, in a high-throughput manner, with NMR spectroscopy."
— Professor Samia Mora, Professor of Medicine, Harvard Medical School; Director, Center for Lipid Metabolomics, Brigham and Women's Hospital

Comparative analysis has shown glycan markers carry information that surpasses traditional risk markers such as C-reactive protein, even when accounting for established clinical risk factors.

"The glycan-based risk score remained significant after we accounted for all of the clinically used risk factors — age, educational level, alcohol intake, physical activity, BMI, waist circumference, hypertension, lipid-lowering drug use, kidney function, total cholesterol, and HDL. This clearly shows that the glycans do carry relevant information that surpasses the traditional risk markers."
— Tamara Štambuk, Senior Researcher, Genos Glycoscience Research Laboratory

This does not mean glycans replace CRP or lipid panels; it means they capture a layer of biological information those tools miss entirely.

Why chronic inflammation is so hard to measure with standard tests

Chronic inflammation is fundamentally different from acute inflammation, and most existing biomarkers are built to catch the acute kind, not the slow-burning kind that drives cardiovascular disease over years. Acute inflammation spikes and resolves; chronic inflammation is quieter and more persistent, and it is inflammaging, a leading contributor to roughly half of all deaths worldwide, that sits behind most age-related cardiovascular pathology.

The problem with standard blood panels is timing. Relying on acute inflammatory markers to understand chronic inflammation only shows you what has already happened, not what has been building quietly for years: a CRP spike tells you inflammation happened, but not whether your immune system has been running hot for the past five years, which is the more relevant question for cardiovascular risk.

Glycosylation is worth distinguishing from a similarly named but biologically distinct process: glycation. Glycosylation is a highly regulated, enzyme-controlled process that enriches protein structure, function, and stability. Glycation, by contrast, is a random, uncontrolled attachment of simple sugars like glucose to a protein, and it damages protein function; it is associated with processes like diabetic complications. Glycosylation is the controlled biological signal, and it is the one GlycanAge measures, with altered glycosylation pathways identified specifically in cardiovascular disease development, underscoring that this is not a side effect of ageing but an active part of the disease process.

Do glycans cause cardiovascular disease, or just reflect it?

This is one of the more genuinely debated questions in the glycobiology of cardiovascular disease, and current evidence points to both directions being true: glycan changes appear to both precede disease onset and shift further as disease processes advance.

Randomized trial data offers some of the clearest evidence on causality. In the Jupiter and TNT statin trials, researchers measured Glyc A before and after statin treatment and found a modest reduction, around 3%, directly attributable to the intervention because the trial design was randomized. Statins, in other words, have a measurable but limited direct effect on this particular glycan signal. Anti-inflammatory treatments such as TNF-alpha inhibitors, used for conditions like rheumatoid arthritis and psoriasis, produce a more substantial reduction in Glyc A, and researchers have used the signal to track disease severity over treatment. Lifestyle interventions show a favourable effect too: weight loss, healthier eating, and increased exercise have been shown to favourably affect glycan structures.

Critically, baseline glycan levels measured years before a cardiovascular event occurred were associated with that future event, supporting the idea that glycan changes are not simply a downstream consequence of disease but mechanistically involved in how it develops, which is what separates glycans from markers that only reflect disease after the fact.

Using glycan testing to track cardiovascular risk in practice

Turning this research into something actionable starts with understanding what a glycan test can and cannot tell you. This is not a diagnostic tool, and it does not detect cardiovascular disease or replace a cardiology work-up; what GlycanAge measures is IgG glycosylation patterns that reflect how much chronic inflammation is present in your immune system right now, giving you and your clinician a signal to track alongside standard risk factors like lipids, blood pressure, and glucose.

The practical workflow is straightforward. A finger-prick blood sample, collected at home, is returned by post and analysed in a lab within two to three weeks. Results appear in a personal dashboard broken into glycan indexes reflecting different aspects of immune ageing, and you can book a 1:1 Result Interpretation Call with a longevity specialist to walk through what the results mean in context, a rising inflammatory signal alongside borderline lipids or blood pressure being a different conversation than either marker in isolation.

How often you retest depends on what you are tracking. For a pharmaceutical intervention, such as a statin or an anti-inflammatory treatment, retesting at 3 to 4 months shows whether that specific treatment is changing your inflammatory biology. For lifestyle changes, such as diet, exercise, or weight loss, a 6 to 12 month window gives the glycan signal time to reflect a sustained shift rather than short-term noise, which matters because, as the research above shows, lipid-lowering interventions have only a modest direct effect on inflammatory glycan signals, while weight loss and anti-inflammatory therapies show a more pronounced one.

For clinicians managing patients with elevated cardiovascular risk, particularly those with a family history, metabolic syndrome, or early signs of hypertension, a baseline test followed by scheduled retests creates a longitudinal record of inflammatory trend rather than a single snapshot, especially relevant given that glycan changes have been observed years ahead of clinical diagnosis in hypertension and type 2 diabetes, both of which compound cardiovascular risk.

What this means for long-term heart health

Cardiovascular risk is not a fixed number handed down by genetics. It is shaped by an active, measurable inflammatory process that begins changing years before disease is diagnosed, and glycans sit at the centre of that process. Track the trend, not just the snapshot: a single cardiovascular risk assessment gives you a moment in time, while repeat glycan testing gives you a trajectory, one that tells you whether your lifestyle changes, medications, or treatment plan are actually shifting the biology that matters.

If you are already managing cardiovascular risk factors, whether through diet, exercise, statins, or another intervention, a glycan test gives you an additional layer of information your standard blood panel does not capture. Explore the Personal Use page to see how GlycanAge fits into a preventive health routine, and order a test kit to establish your baseline before your next intervention.

Chronic inflammation builds years before cardiovascular symptoms appear. Measure it now, and track whether your next lifestyle or treatment change is actually working.

Order Your Test Kit

External sources

• Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3(5):e001221. DOI: 10.1161/JAHA.114.001221 Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC4323825/

• Menni C, Gudelj I, Macdonald-Dunlop E, et al. Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated With Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts. Circ Res. 2018;122(11):1555-1564. Link: https://pubmed.ncbi.nlm.nih.gov/29535164/

• Kifer D, Louca P, Cvetko A, et al. N-glycosylation of immunoglobulin G predicts incident hypertension. J Hypertens. 2021;39(12):2527-2533. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7611954/

• Birukov A, Plavsa B, Eichelmann F, et al. Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease. Diabetes Care. 2022;45(11):2729-2736. Link: https://pubmed.ncbi.nlm.nih.gov/36174116/

• Wittenbecher C, Štambuk T, Kuxhaus O, et al. Plasma N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020;43(3):661-668. Link: https://pubmed.ncbi.nlm.nih.gov/31915204/

• Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: The human N-glycome. Biochim Biophys Acta. 2016;1860(8):1574-1582. Link: https://pubmed.ncbi.nlm.nih.gov/26500099/

• Hoshi RA, Plavsa B, Liu Y, et al. N-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular Events. Circ Res. 2024;134(5):e3-e14. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10923145/